Literature DB >> 2427658

Changes of neurotransmitter systems in chronic relapsing experimental allergic encephalomyelitis in rat brain and spinal cord.

W Krenger, C G Honegger, C Feurer, S Cammisuli.   

Abstract

Catecholamine and indoleamine neurotransmitters, together with some of their precursors and metabolites, were determined using HPLC in three brain and two spinal cord regions of Lewis rats with chronic relapsing allergic encephalomyelitis and of control rats injected with complete Freund's adjuvant. Three attacks and two recovery phases were investigated. Changes are found mainly in the spinal cord. In the lumbosacral region both 5-hydroxytryptamine and noradrenaline are reduced during the entire course of the disease, whereas in the craniothoracal region 5-hydroxytryptamine is unchanged and only noradrenaline is reduced during the attacks, returning to normal during the first recovery. The precursors tyrosine and tryptophan are greatly elevated during the first two attacks in both regions. The 5-hydroxytryptamine turnover marker 5-hydroxyindoleacetic acid is increased in the first attack in both regions, then it decreases in the later stages, indicating destruction of nerve fibers. On the fourth and seventh days after inoculation values are generally not significantly different from controls in all regions. The possible correlation of neurochemical results with neurological signs is discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2427658     DOI: 10.1111/j.1471-4159.1986.tb00747.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  5 in total

1.  Locus coeruleus damage and noradrenaline reductions in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  Paul E Polak; Sergey Kalinin; Douglas L Feinstein
Journal:  Brain       Date:  2011-02-04       Impact factor: 13.501

Review 2.  Mast cell specific proteases in rat brain: changes in rats with experimental allergic encephalomyelitis.

Authors:  A Rouleau; V Dimitriadou; M D Trung Tuong; G F Newlands; H R Miller; J C Schwartz; M Garbarg
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

3.  Increasing CNS noradrenaline reduces EAE severity.

Authors:  Maria Vittoria Simonini; Paul E Polak; Anthony Sharp; Susan McGuire; Elena Galea; Douglas L Feinstein
Journal:  J Neuroimmune Pharmacol       Date:  2009-12-04       Impact factor: 4.147

4.  Noradrenergic regulation of glial activation: molecular mechanisms and therapeutic implications.

Authors:  David Braun; Jose L M Madrigal; Douglas L Feinstein
Journal:  Curr Neuropharmacol       Date:  2014-07       Impact factor: 7.363

5.  Role of catalpol in ameliorating the pathogenesis of experimental autoimmune encephalomyelitis by increasing the level of noradrenaline in the locus coeruleus.

Authors:  Qian Li; Tao Yang; An-Chen Guo; Yong-Ping Fan
Journal:  Mol Med Rep       Date:  2018-01-05       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.